a deadly restaurant fire in madrid. two people have died and at least ten others are injured. you re watching bbc news. now its time for sportsday with chetan pathak hello and welcome to sportsday i m chetan pathak coming up on tonight s programme: a huge win for leicester in their fight for premier league survival they re out of the bottom three down but not out chelsea are narrowly beaten by barcelona in the first leg of their champions league semi final eight tries for england who thrash ireland to stay on course for a grand slam in the women s six nations also coming up on sportsday tonight. into the quarter the finals of the world snooker championship the rocket ronnie o sullivan blasts his way past hossein vafei welcome along this saturday night, thank you forjoining us. we start with the fight for survival in the premier league more on a huge win for leicester to come but the day started with a missed opportunity for leeds. they could have pulled clear o
(Reuters) -X4 Pharmaceuticals said on Monday the U.S. FDA has approved its therapy to treat a rare genetic immunodeficiency disease in patients 12 years of age and older, sending its shares up 16% before the bell. X4's mavorixafor, which will be sold under the brand name Xolremdi, is the first therapy to get U.S. approval specifically for the treatment of WHIM syndrome. WHIM is characterized by disorders in which the body's immune system does not function properly.
The study's findings suggest that high baseline white blood cell count, particularly high neutrophil count, was associated with a higher incidence of long-term acute exacerbation of chronic obstructive pulmonary disease (COPD).
Compared with a single dose, more patients in the split-dose group had improved disease activity at 16 weeks, and fewer needed additional DMARDs, but the effect was not found at 24 weeks.